Enanta Pharmaceuticals Inc
ENTA
Get informed when a big investor buys or sells
+ FollowMarket Cap$350.8M
Close$
$-7.91
152.3% downside
Current Fair Value
152.3% downsideOvervalued by 152.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $350.80 Million |
|---|---|
| Enterprise Value | $502.49 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.84 |
| Beta | 0.99 |
| Outstanding Shares | 21,380,000 |
Return
| Return on Equity | -53.17% |
|---|---|
| Return on Assets | -19.70% |
| Return on Invested Capital | -19.63% |
Valuation & Multiples
| P/E Ratio | -5.51 |
|---|---|
| PEG | 13.07 |
| Price to Sales | 5.04 |
| Price to Book Ratio | 3.02 |
| Enterprise Value to Revenue | 7.26 |
| Enterprise Value to EBIT | -9.54 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.37 |
| Debt to Equity | 1.6 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
$17.03 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
$17.40 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3812▲ 38.12% |
|---|---|
| Total Calls | 38,300▼ 67.43% |
| Total Puts | 14,600▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 125.22%▲ 33.43% |
|---|---|
| Total Invested | $338.10M▼ 18.74% |
| Investors Holding | 134▲ 2.00% |
ESG Score
No data
About Enanta Pharmaceuticals Inc
CEO: Jay Luly